Sumary of Pfizer planning to seek approval for their COVID-19 vaccine in children aged five and older:
- ‘In the coming weeks, we will present the results of our study on the five-to-11-year- olds worldwide to the authorities and apply for approval of the vaccine for this age group,’ Türeci said.
- ‘ Pictured: A Pfizer COVID-19 vial at a mobile clinic in East Los Angeles, July 2021 Dr Özlem Türeci, chief physician for BioNTech, said the vaccine is the same as that approved for adolescents and adults, but a smaller dose.
- The team will test the safety, tolerability immune response generated by the vaccine, by drawing blood prior to dose 1 and six months after dose 2. If the vaccine is proven to be safe and effective, the trial will be unblinded at the six-month follow-up, meaning those who received the placebo will be allowed to get the inoculation.
- Their bodies and immune systems behave differently, meaning they might have different treatment needs.